Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the submission of ...
Collaboration aims to leverage Polyrizon’s advanced proprietary intranasal delivery platform to support clinical development of Clearmind’s drug candidate proprietary MEAI The collaboration between ...
For those suffering from treatment-resistant depression, the anesthetic drug ketamine offers hope, but it has side effects and can be costly to access—a University of Otago-led clinical trial may ...
Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today ...
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its proprietary nasal delivery system is being ...
Market Movers Investor Summit May 5, 2026, New York, NY Chief Financial Officer Eyal Rubin will participate in 1x1 meetings. D. Boral Capital Global Conference May 7, 2026, New York, NY Chief ...
The Gazette offers audio versions of articles using Instaread. Some words may be mispronounced. The U.S. Food and Drug Administration on Tuesday said it approved a Johnson & Johnson nasal spray ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results